Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2019-11-25 Capital/Financing Update
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to a shelf registration statement on Form S-3. It details an offering of common stock, pre-funded warrants, and Class B warrants, including terms of the offering, underwriting details, risk factors, and use of proceeds. The document is a detailed offering prospectus supplement and accompanying prospectus, which is a type of capital raising document. It is not a financial report, earnings release, management discussion, or regulatory filing unrelated to capital raising. The presence of underwriting information, offering terms, and securities descriptions clearly indicate this is a Capital/Financing Update filing. The document length (15,000 characters) and content confirm it is the actual offering document, not just an announcement or a brief summary. Therefore, the correct classification is Capital/Financing Update (CAP).
2019-11-25 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 14, 2019. It reports the entry into a material definitive lease agreement and the creation of a direct financial obligation related to that lease. The content focuses on lease terms, rent commencement, tenant improvements, and security deposits. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is a regulatory announcement of a material event (lease agreement and financial obligation) rather than a full financial report. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as lease obligations.
2019-11-14 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2019, for X4 Pharmaceuticals, Inc. It announces the issuance of a press release with financial results and business highlights for the quarter ended September 30, 2019. The document explicitly states that the press release is being furnished as an exhibit and is not filed as part of the report. The length is 3360 characters, which is relatively short and consistent with a current report filing rather than a full financial report. The content is primarily an announcement of financial results via a press release, not the full earnings release itself. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a current report announcing the release of financial results but does not contain the full earnings release or detailed financial data itself.
2019-11-07 English
FORM 3 SUBMISSION
Director's Dealing
2019-11-06 English
8-K/A
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A, an amendment to a previously filed Form 8-K, which is a current report filed with the SEC to disclose material events. The content specifically details the appointment of a new director to the Board and his committee assignment. This fits the category of announcements related to changes in the company's board of directors or senior management. The document is not a full report like an Annual Report or Interim Report, nor is it a voting result or financial release. Therefore, it is best classified as Board/Management Information (MANG). The document length is under 5,000 characters and contains substantive information about management changes, not just a report publication announcement or certification. Confidence is high due to clear identification of director appointment and committee assignment.
2019-10-18 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.